Characterization of immune responses induced by immunization with the HA DNA vaccines of two antigenically distinctive H5N1 HPAIV isolates

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Gao, Yulong ^a,b   Wen, Zhiyuan ^a,b   Dong, Ke ^b,c   Zhong, Gongxun ^a   Wang, Xiaomei ^a   Bu, Zhigao ^a   Chen, Hualan ^a   Ye, Ling ^b   Yang, Chinglai ^b  

^a INSTITUTE OF PLANT PROTECTION   (China)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; QH HA DNA VACCINE; SX HA DNA VACCINE; UNCLASSIFIED DRUG; VIRUS HEMAGGLUTININ;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS REACTION; DNA IMMUNIZATION; DNA PURIFICATION; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; PANDEMIC; T LYMPHOCYTE RECEPTOR GENE; VIRUS ISOLATION; VIRUS STRAIN;

ADAPTIVE IMMUNITY; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CHICKENS; EPITOPES, T-LYMPHOCYTE; FEMALE; GEESE; HELA CELLS; HEMAGGLUTININS, VIRAL; HUMANS; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES; VACCINATION; VACCINES, DNA;

AVIAN INFLUENZA VIRUS;

EID: 84864447119     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041332     Document Type: Article

References (67)

1. Bridges CB, Harper SA, Fukuda K, Uyeki TM, Cox NJ,et al. ((2003)) Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 52: 1-34; quiz CE31-34.
2. Osterholm MT, ((2005)) Preparing for the next pandemic. N Engl J Med 352: 1839-1842.
3. Cox RJ, Brokstad KA, Ogra P, ((2004)) Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 59: 1-15.
4. Kilbourne ED, ((2006)) Influenza pandemics of the 20th century. Emerg Infect Dis 12: 9-14.
5. WHO (2009) Transcript of statement by Margaret Chan, Director-General of the World Health Organization. 11 June 2009. WHO website. Available: http://www.who.int/mediacentre/influenzaAH1N1_presstranscript_20090611.pdf. Accessed 2012 Jul 7.
6. Khan K, Arino J, Hu W, Raposo P, Sears J, et al. ((2009)) Spread of a novel influenza A (H1N1) virus via global airline transportation. N Engl J Med 361: 212-214.
7. Smith GJ, Vijaykrishna D, Bahl J, Lycett SJ, Worobey M, et al. ((2009)) Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 459: 1122-1125.
8. Yen H, Webster RG, ((2009)) pandemic influenza as a current threat. Current Topics in Microbiology and Immunology 333: 3-24.
9. Claas EC, Osterhaus AD, van Beek R, De Jong JC, Rimmelzwaan GF, et al. ((1998)) Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 351: 472-477.
10. Subbarao K, Klimov A, Katz J, Regnery H, Lim W, et al. ((1998)) Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 279: 393-396.
11. Chen H, Deng G, Li Z, Tian G, Li Y, et al. ((2004)) The evolution of H5N1 influenza viruses in ducks in southern China. Proc Natl Acad Sci U S A 101: 10452-10457.
12. Guan Y, Peiris JS, Lipatov AS, Ellis TM, Dyrting KC, et al. ((2002)) Emergence of multiple genotypes of H5N1 avian influenza viruses in Hong Kong SAR. Proc Natl Acad Sci U S A 99: 8950-8955.
13. Webster RG, Guan Y, Peiris M, Walker D, Krauss S, et al. ((2002)) Characterization of H5N1 influenza viruses that continue to circulate in geese in southeastern China. J Virol 76: 118-126.
14. Sturm-Ramirez KM, Ellis T, Bousfield B, Bissett L, Dyrting K, et al. ((2004)) Reemerging H5N1 influenza viruses in Hong Kong in 2002 are highly pathogenic to ducks. J Virol 78: 4892-4901.
15. WHO (2012) Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003-2012. Influenza at the Human-Animal Interface. WHO website. Available: http://www.who.int/influenza/human_animal_interface/EN_GIP_2012 0502CumulativeNumberH5N1cases.pdf. Accessed 2012 Jul 7.
16. Wu WL, Chen Y, Wang P, Song W, Lau SY, et al. ((2008)) Antigenic profile of avian H5N1 viruses in Asia from 2002 to 2007. J Virol 82: 1798-1807.
17. O'Neill E, Donis RO, ((2009)) Generation and characterization of candidate vaccine viruses for prepandemic influenza vaccines. Current Topics in Microbiology and Immunology 333: 83-108.
18. WHO ((2008)) Toward a unified nomenclature system for highly pathogenic avian influenza virus (H5N1). Emerg Infect Dis 14: e1.
19. Li Y, Shi J, Zhong G, Deng G, Tian G, et al. ((2010)) Continued evolution of H5N1 influenza viruses in wild birds, domestic poultry, and humans in China from 2004 to 2009. J Virol 84: 8389-8397.
20. Chen H, Li Y, Li Z, Shi J, Shinya K, et al. ((2006)) Properties and dissemination of H5N1 viruses isolated during an influenza outbreak in migratory waterfowl in western China. J Virol 80: 5976-5983.
21. Chen H, Bu Z, ((2009)) Development and application of avain influenza vaccines in China. Current Topics in Microbiology and Immunology 333: 153-162.
22. Boon ACM, Webby RJ, ((2009)) Antigenic cross-reactivity among H5N1 viruses. Current Topics in Microbiology and Immunology 333: 25-40.
23. Ducatez MF, Olinger CM, Owoade AA, Tarnagda Z, Tahita MC, et al. ((2007)) Molecular and antigenic evolution and geographical spread of H5N1 highly pathogenic avian influenza viruses in western Africa. J Gen Virol 88: 2297-2306.
24. Lee YJ, Choi YK, Kim YJ, Song MS, Jeong OM, et al. ((2008)) Highly pathogenic avian influenza virus (H5N1) in domestic poultry and relationship with migratory birds, South Korea. Emerg Infect Dis 14: 487-490.
25. Siengsanan J, Chaichoune K, Phonaknguen R, Sariya L, Prompiram P, et al. ((2009)) Comparison of outbreaks of H5N1 highly pathogenic avian influenza in wild birds and poultry in Thailand. J Wildl Dis 45: 740-747.
26. Weber S, Harder T, Starick E, Beer M, Werner O, et al. ((2007)) Molecular analysis of highly pathogenic avian influenza virus of subtype H5N1 isolated from wild birds and mammals in northern Germany. J Gen Virol 88: 554-558.
27. Zhou J, Sun W, Wang J, Guo J, Yin W, et al. ((2009)) Characterization of the H5N1 highly pathogenic avian influenza virus derived from wild pikas in China. J Virol 83: 8957-8964.
28. Steel J, Lowen AC, Mubareka S, Palese P, ((2009)) Transmission of influenza virus in a mammalian host is increased by PB2 amino acids 627K or 627E/701N. PLoS Pathog 5: e1000252.
29. Gao Y, Zhang Y, Shinya K, Deng G, Jiang Y, et al. ((2009)) Identification of amino acids in HA and PB2 critical for the transmission of H5N1 avian influenza viruses in a mammalian host. PLoS Pathog 5: e1000709.
30. Nguyen T, Davis CT, Stembridge W, Shu B, Balish A, et al. ((2009)) Characterization of a highly pathogenic avian influenza H5N1 virus sublineage in poultry seized at ports of entry into Vietnam. Virology 387: 250-256.
31. Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, Hayden FG, Nguyen DH, et al. ((2008)) Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 358: 261-273.
32. Kim JH, Skountzou I, Compans R, Jacob J, ((2009)) Original antigenic sin responses to influenza viruses. J Immunol 183: 3294-3301.
33. Davenport FM, Hennessy AV, Francis T Jr, ((1953)) Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus. J Exp Med 98: 641-656.
34. Jensen KE, Francis T Jr, ((1953)) The antigenic composition of influenza virus measured by antibody-absorption. J Exp Med 98: 619-639.
35. Francis T Jr, Davenport FM, Hennessy AV, ((1953)) A serological recapitulation of human infection with different strains of influenza virus. Trans Assoc Am Physicians 66: 231-239.
36. Angelova LA, Shvartsman Ya S, ((1982)) Original antigenic sin to influenza in rats. Immunology 46: 183-188.
37. Davenport FM, Hennessy AV, ((1956)) A serologic recapitulation of past experiences with influenza A; antibody response to monovalent vaccine. J Exp Med 104: 85-97.
38. Fazekas de St G, Webster RG, ((1966)) Disquisitions on Original Antigenic Sin. II. Proof in lower creatures. J Exp Med 124: 347-361.
39. Fazekas de St G, Webster RG, ((1966)) Disquisitions of Original Antigenic Sin. I. Evidence in man. J Exp Med 124: 331-345.
40. Hennessy AV, Davenport FM, Francis T Jr, ((1955)) Studies of antibodies to strains of influenza virus in persons of different ages in sera collected in a postepidemic period. J Immunol 75: 401-409.
41. Jensen KE, Davenport FM, Hennessy AV, Francis T Jr, ((1956)) Characterization of influenza antibodies by serum absorption. J Exp Med 104: 199-209.
42. Virelizier JL, Allison AC, Schild GC, ((1974)) Antibody responses to antigenic determinants of influenza virus hemagglutinin. II. Original antigenic sin: a bone marrow-derived lymphocyte memory phenomenon modulated by thymus-derived lymphocytes. J Exp Med 140: 1571-1578.
43. Virelizier JL, Postlethwaite R, Schild GC, Allison AC, ((1974)) Antibody responses to antigenic determinants of influenza virus hemagglutinin. I. Thymus dependence of antibody formation and thymus independence of immunological memory. J Exp Med 140: 1559-1570.
44. Webster RG, ((1966)) Original antigenic sin in ferrets: the response to sequential infections with influenza viruses. J Immunol 97: 177-183.
45. Yarchoan R, Nelson DL, ((1984)) Specificity of in vitro anti-influenza virus antibody production by human lymphocytes: analysis of original antigenic sin by limiting dilution cultures. J Immunol 132: 928-935.
46. Haaheim LR, ((2003)) Original antigenic sin. A confounding issue? Dev Biol (Basel) 115: 49-53.
47. Klinman NR, Press JL, Segal GP, ((1973)) Overlap stimulation of primary and secondary B cells by cross-reacting determinants. J Exp Med 138: 1276-1281.
48. Fish S, Zenowich E, Fleming M, Manser T, ((1989)) Molecular analysis of original antigenic sin. I. Clonal selection, somatic mutation, and isotype switching during a memory B cell response. J Exp Med 170: 1191-1209.
49. Wrammert J, Smith K, Miller J, Langley WA, Kokko K, et al. ((2008)) Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453: 667-671.
50. CDC ((2009)) Update: Novel Influenza A (H1N1) Virus Infections-Worldwide, May 6, 2009 (Reprinted from MMWR., vol 58, pg 453-458, 2009). Jama-Journal of the American Medical Association 301: 2319-2321.
51. Adalja AA, Henderson DA, ((2009)) Original antigenic sin and pandemic (H1N1). Emerg Infect Dis 16: 1028-1029.
52. Skowronski DM, De Serres G, Crowcroft NS, Janjua NZ, Boulianne N, et al. ((2010)) Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada. PLoS Med 7: e1000258.
53. Janjua NZ, Skowronski DM, Hottes TS, Osei W, Adams E, et al. ((2010)) Seasonal influenza vaccine and increased risk of pandemic A/H1N1-related illness: first detection of the association in British Columbia, Canada. Clin Infect Dis 51: 1017-1027.
54. Crum-Cianflone NF, Blair PJ, Faix D, Arnold J, Echols S, et al. ((2009)) Clinical and epidemiologic characteristics of an outbreak of novel H1N1 (swine origin) influenza A virus among United States military beneficiaries. Clin Infect Dis 49: 1801-1810.
55. Garcia-Garcia L, Valdespino-Gomez JL, Lazcano-Ponce E, Jimenez-Corona A, Higuera-Iglesias A, et al. ((2009)) Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case-control study in Mexico City. BMJ 339: b3928.
56. Echevarria-Zuno S, Mejia-Arangure JM, Mar-Obeso AJ, Grajales-Muniz C, Robles-Perez E, et al. ((2009)) Infection and death from influenza A H1N1 virus in Mexico: a retrospective analysis. Lancet 374: 2072-2079.
57. Kelly H, Grant K (2009) Interim analysis of pandemic influenza (H1N1) 2009 in Australia: surveillance trends, age of infection and effectiveness of seasonal vaccination. Euro Surveill 14.
58. Iuliano AD, Reed C, Guh A, Desai M, Dee DL, et al. ((2009)) Notes from the field: outbreak of 2009 pandemic influenza A (H1N1) virus at a large public university in Delaware, April-May 2009. Clin Infect Dis 49: 1811-1820.
59. Lessler J, Reich NG, Cummings DA, Nair HP, Jordan HT, et al. ((2009)) Outbreak of 2009 pandemic influenza A (H1N1) at a New York City school. N Engl J Med 361: 2628-2636.
60. Valkenburg SA, Rutigliano JA, Ellebedy AH, Doherty PC, Thomas PG, et al. ((2011)) Immunity to seasonal and pandemic influenza A viruses. Microbes Infect 13: 489-501.
61. Wang S, Hackett A, Jia N, Zhang C, Zhang L, et al. ((2011)) Polyvalent DNA Vaccines Expressing HA Antigens of H5N1 Influenza Viruses with an Optimized Leader Sequence Elicit Cross-Protective Antibody Responses. PLoS One 6: e28757.
62. Giles BM, Bissel SJ, Dealmeida DR, Wiley CA, Ross TM (2011) Antibody Breadth and Protective Efficacy Is Increased by Vaccination with Computationally Optimized Hemagglutinin but Not with Polyvalent Hemagglutinin Based H5n1 Vlp Vaccines. Clin Vaccine Immunol.
63. Wen Z, Ye L, Gao Y, Pan L, Dong K, et al. ((2009)) Immunization by influenza virus-like particles protects aged mice against lethal influenza virus challenge. Antiviral Res 84: 215-224.
64. Ge J, Deng G, Wen Z, Tian G, Wang Y, et al. ((2007)) Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses. J Virol 81: 150-158.
65. Zhu Q, Zarnitsyn VG, Ye L, Wen Z, Gao Y, et al. ((2009)) Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge. Proc Natl Acad Sci U S A 106: 7968-7973.
66. Ye L, Bu Z, Vzorov A, Taylor D, Compans RW, et al. ((2004)) Surface stability and immunogenicity of the human immunodeficiency virus envelope glycoprotein: role of the cytoplasmic domain. J Virol 78: 13409-13419.
67. Bu Z, Ye L, Vzorov A, Taylor D, Compans RW, et al. ((2004)) Enhancement of immunogenicity of an HIV Env DNA vaccine by mutation of the Tyr-based endocytosis motif in the cytoplasmic domain. Virology 328: 62-73.